▶ 調査レポート

便中カルプロテクチン検査のグローバル市場(2023-2031年):大人、小児

• 英文タイトル:Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA [Enzyme Linked Immunosorbent Assay], Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが調査・発行した産業分析レポートです。便中カルプロテクチン検査のグローバル市場(2023-2031年):大人、小児 / Fecal Calprotectin Test Market (Patient Type: Adult and Pediatric; Assay Type: ELISA [Enzyme Linked Immunosorbent Assay], Enzyme Fluoroimmunoassay, and Quantitative Immune-chromatography) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 / MRC2307A0203資料のイメージです。• レポートコード:MRC2307A0203
• 出版社/出版日:Transparency Market Research / 2023年5月
• レポート形態:英文、PDF、203ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の市場調査資料によると、世界の便中カルプロテクチン検査市場規模は2023年の126.9百万ドルから2031年には355.8百万ドルへ上り、予想期間中、年平均10.7%拡大すると予測されています。本調査資料では、便中カルプロテクチン検査の世界市場を調査・分析し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要洞察、患者種類別(大人、小児)分析、アッセイ種類別(ELISA(酵素結合免疫吸着測定法)、酵素フルオロイムノアッセイ、定量的免疫クロマトグラフィー)分析、疾患別(炎症性腸疾患、大腸がん、セリアック病)分析、エンドユーザー別(病院、診断研究所、学術・研究機関)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況などについて明らかにしています。なお、本書に記載されている企業情報には、Abbexa、ALPCO、Alpha Laboratories、Biomerica、BÜHLMANN Laboratories AG、DRG Instruments GmbH、EagleBio、Epitope Diagnostics, Inc.、OPERON, S.A.、R-Biopharm AG、Svar Life Science、Thermo Fisher Scientific Inc.、Werfen、SENTINEL CH. SpA、Diazyme Laboratories, Inc.などが含まれています。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要洞察
・世界の便中カルプロテクチン検査市場規模:患者種類別
- 大人における市場規模
- 小児における市場規模
・世界の便中カルプロテクチン検査市場規模:アッセイ種類別
- ELISA(酵素結合免疫吸着測定法)における市場規模
- 酵素フルオロイムノアッセイにおける市場規模
- 定量的免疫クロマトグラフィーにおける市場規模
・世界の便中カルプロテクチン検査市場規模:疾患別
- 炎症性腸疾患における市場規模
- 大腸がんにおける市場規模
- セリアック病における市場規模
・世界の便中カルプロテクチン検査市場規模:エンドユーザー別
- 病院における市場規模
- 診断研究所における市場規模
- 学術・研究機関における市場規模
・世界の便中カルプロテクチン検査市場規模:地域別
- 北米の便中カルプロテクチン検査市場規模
- ヨーロッパの便中カルプロテクチン検査市場規模
- アジア太平洋の便中カルプロテクチン検査市場規模
- 中南米の便中カルプロテクチン検査市場規模
- 中東・アフリカの便中カルプロテクチン検査市場規模
・競争状況

Fecal Calprotectin Test Market – Scope of Report
TMR’s report on the global Fecal Calprotectin Test market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Fecal Calprotectin Test market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Fecal Calprotectin Test market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Fecal Calprotectin Test market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Fecal Calprotectin Test market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Fecal Calprotectin Test market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Fecal Calprotectin Test market.

The report delves into the competitive landscape of the global Fecal Calprotectin Test market. Key players operating in the global Fecal Calprotectin Test market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Fecal Calprotectin Test market profiled in this report.

Key Questions Answered in Global Fecal Calprotectin Test Market Report
• What is the sales/revenue generated by Fecal Calprotectin Test across all regions during the forecast period?
• What are the opportunities in the global Fecal Calprotectin Test market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Fecal Calprotectin Test Market – Research Objectives and Research Approach
The comprehensive report on the global Fecal Calprotectin Test market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Fecal Calprotectin Test market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Fecal Calprotectin Test market.

レポート目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Fecal Calprotectin Test Market
4. Market Overview
    4.1. Introduction
        4.1.1. Patient Type Definition
        4.1.2. Industry Evolution / Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Fecal Calprotectin Test Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Technological Advancement
    5.2. Diseases Epidemiology
    5.3. Regulatory Scenario
    5.4. Pricing Analysis
    5.5. COVID-19 Impact Analysis
6. Global Fecal Calprotectin Test Market Analysis and Forecast, by Patient Type
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Patient Type, 2017-2031
        6.3.1. Adult
        6.3.2. Pediatric
    6.4. Market Attractiveness Analysis, by Patient Type
7. Global Fecal Calprotectin Test Market Analysis and Forecast, by Assay Type
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Assay Type, 2017-2031
        7.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        7.3.2. Enzyme Fluoroimmunoassay
        7.3.3. Quantitative Immune-chromatography
    7.4. Market Attractiveness Analysis, by Assay Type
8. Global Fecal Calprotectin Test Market Analysis and Forecast, by Indication
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Indication, 2017-2031
        8.3.1. Inflammatory Bowel Disease
        8.3.2. Colorectal Cancer
        8.3.3. Celiac Disease
    8.4. Market Attractiveness Analysis, by Indication
9. Global Fecal Calprotectin Test Market Analysis and Forecast, by End-user
    9.1. Introduction & Definition
    9.2. Key Findings / Developments
    9.3. Market Value Forecast, by End-user, 2017-2031
        9.3.1. Hospitals
        9.3.2. Diagnostic Laboratories
        9.3.3. Academic & Research Institutes
    9.4. Market Attractiveness Analysis, by End-user
10. Global Fecal Calprotectin Test Market Analysis and Forecast, by Region
    10.1. Key Findings
    10.2. Market Value Forecast, by Region
        10.2.1. North America
        10.2.2. Europe
        10.2.3. Asia Pacific
        10.2.4. Latin America
        10.2.5. Middle East & Africa
    10.3. Market Attractiveness Analysis, by Region
11. North America Fecal Calprotectin Test Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Patient Type, 2017-2031
        11.2.1. Adult
        11.2.2. Pediatric
    11.3. Market Value Forecast, by Assay Type, 2017-2031
        11.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        11.3.2. Enzyme Fluoroimmunoassay
        11.3.3. Quantitative Immune-chromatography
    11.4. Market Value Forecast, by Indication, 2017-2031
        11.4.1. Inflammatory Bowel Disease
        11.4.2. Colorectal Cancer
        11.4.3. Celiac Disease
    11.5. Market Value Forecast, by End-user, 2017-2031
        11.5.1. Hospitals
        11.5.2. Diagnostic Laboratories
        11.5.3. Academic & Research Institutes
    11.6. Market Value Forecast, by Country, 2017-2031
        11.6.1. U.S.
        11.6.2. Canada
    11.7. Market Attractiveness Analysis
        11.7.1. By Patient Type
        11.7.2. By Assay Type
        11.7.3. By Indication
        11.7.4. By End-user
        11.7.5. By Country
12. Europe Fecal Calprotectin Test Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Patient Type, 2017-2031
        12.2.1. Adult
        12.2.2. Pediatric
    12.3. Market Value Forecast, by Assay Type, 2017-2031
        12.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        12.3.2. Enzyme Fluoroimmunoassay
        12.3.3. Quantitative Immune-chromatography
    12.4. Market Value Forecast, by Indication, 2017-2031
        12.4.1. Inflammatory Bowel Disease
        12.4.2. Colorectal Cancer
        12.4.3. Celiac Disease
    12.5. Market Value Forecast, by End-user, 2017-2031
        12.5.1. Hospitals
        12.5.2. Diagnostic Laboratories
        12.5.3. Academic & Research Institutes
    12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.6.1. Germany
        12.6.2. U.K.
        12.6.3. France
        12.6.4. Italy
        12.6.5. Spain
        12.6.6. Rest of Europe
    12.7. Market Attractiveness Analysis
        12.7.1. By Patient Type
        12.7.2. By Assay Type
        12.7.3. By Indication
        12.7.4. By End-user
        12.7.5. By Country/Sub-region
13. Asia Pacific Fecal Calprotectin Test Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Patient Type, 2017-2031
        13.2.1. Adult
        13.2.2. Pediatric
    13.3. Market Value Forecast, by Assay Type, 2017-2031
        13.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        13.3.2. Enzyme Fluoroimmunoassay
        13.3.3. Quantitative Immune-chromatography
    13.4. Market Value Forecast, by Indication, 2017-2031
        13.4.1. Inflammatory Bowel Disease
        13.4.2. Colorectal Cancer
        13.4.3. Celiac Disease
    13.5. Market Value Forecast, by End-user, 2017-2031
        13.5.1. Hospitals
        13.5.2. Diagnostic Laboratories
        13.5.3. Academic & Research Institutes
    13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        13.6.1. China
        13.6.2. Japan
        13.6.3. India
        13.6.4. Australia & New Zealand
        13.6.5. Rest of Asia Pacific
    13.7. Market Attractiveness Analysis
        13.7.1. By Patient Type
        13.7.2. By Assay Type
        13.7.3. By Indication
        13.7.4. By End-user
        13.7.5. By Country/Sub-region
14. Latin America Fecal Calprotectin Test Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Patient Type, 2017-2031
        14.2.1. Adult
        14.2.2. Pediatric
    14.3. Market Value Forecast, by Assay Type, 2017-2031
        14.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        14.3.2. Enzyme Fluoroimmunoassay
        14.3.3. Quantitative Immune-chromatography
    14.4. Market Value Forecast, by Indication, 2017-2031
        14.4.1. Inflammatory Bowel Disease
        14.4.2. Colorectal Cancer
        14.4.3. Celiac Disease
    14.5. Market Value Forecast, by End-user, 2017-2031
        14.5.1. Hospitals
        14.5.2. Diagnostic Laboratories
        14.5.3. Academic & Research Institutes
    14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.6.1. Brazil
        14.6.2. Mexico
        14.6.3. Rest of Latin America
    14.7. Market Attractiveness Analysis
        14.7.1. By Patient Type
        14.7.2. By Assay Type
        14.7.3. By Indication
        14.7.4. By End-user
        14.7.5. By Country/Sub-region
15. Middle East & Africa Fecal Calprotectin Test Market Analysis and Forecast
    15.1. Introduction
        15.1.1. Key Findings
    15.2. Market Value Forecast, by Patient Type, 2017-2031
        15.2.1. Adult
        15.2.2. Pediatric
    15.3. Market Value Forecast, by Assay Type, 2017-2031
        15.3.1. ELISA (Enzyme linked Immunosorbent Assay)
        15.3.2. Enzyme Fluoroimmunoassay
        15.3.3. Quantitative Immune-chromatography
    15.4. Market Value Forecast, by Indication, 2017-2031
        15.4.1. Inflammatory Bowel Disease
        15.4.2. Colorectal Cancer
        15.4.3. Celiac Disease
    15.5. Market Value Forecast, by End-user, 2017-2031
        15.5.1. Hospitals
        15.5.2. Diagnostic Laboratories
        15.5.3. Academic & Research Institutes
    15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
        15.6.1. GCC Countries
        15.6.2. South Africa
        15.6.3. Rest of Middle East & Africa
    15.7. Market Attractiveness Analysis
        15.7.1. By Patient Type
        15.7.2. By Assay Type
        15.7.3. By Indication
        15.7.4. By End-user
        15.7.5. By Country/Sub-region
16. Competition Landscape
    16.1. Market Player – Competitive Matrix (by tier and size of companies)
    16.2. Market Share Analysis, by Company (2022)
    16.3. Company Profiles
        16.3.1. Abbexa
            16.3.1.1. Company Overview
            16.3.1.2. Drug Class Portfolio
            16.3.1.3. SWOT Analysis
            16.3.1.4. Financial Overview
            16.3.1.5. Strategic Overview
        16.3.2. ALPCO
            16.3.2.1. Company Overview
            16.3.2.2. Drug Class Portfolio
            16.3.2.3. SWOT Analysis
            16.3.2.4. Financial Overview
            16.3.2.5. Strategic Overview
        16.3.3. Alpha Laboratories
            16.3.3.1. Company Overview
            16.3.3.2. Drug Class Portfolio
            16.3.3.3. SWOT Analysis
            16.3.3.4. Financial Overview
            16.3.3.5. Strategic Overview
        16.3.4. Biomerica
            16.3.4.1. Company Overview
            16.3.4.2. Drug Class Portfolio
            16.3.4.3. SWOT Analysis
            16.3.4.4. Financial Overview
            16.3.4.5. Strategic Overview
        16.3.5. BÜHLMANN Laboratories AG
            16.3.5.1. Company Overview
            16.3.5.2. Drug Class Portfolio
            16.3.5.3. SWOT Analysis
            16.3.5.4. Financial Overview
            16.3.5.5. Strategic Overview
        16.3.6. DRG Instruments GmbH
            16.3.6.1. Company Overview
            16.3.6.2. Drug Class Portfolio
            16.3.6.3. SWOT Analysis
            16.3.6.4. Financial Overview
            16.3.6.5. Strategic Overview
        16.3.7. EagleBio
            16.3.7.1. Company Overview
            16.3.7.2. Drug Class Portfolio
            16.3.7.3. SWOT Analysis
            16.3.7.4. Financial Overview
            16.3.7.5. Strategic Overview
        16.3.8. Epitope Diagnostics, Inc.
            16.3.8.1. Company Overview
            16.3.8.2. Drug Class Portfolio
            16.3.8.3. SWOT Analysis
            16.3.8.4. Financial Overview
            16.3.8.5. Strategic Overview
        16.3.9. OPERON, S.A.
            16.3.9.1. Company Overview
            16.3.9.2. Drug Class Portfolio
            16.3.9.3. SWOT Analysis
            16.3.9.4. Financial Overview
            16.3.9.5. Strategic Overview
        16.3.10. R-Biopharm AG
            16.3.10.1. Company Overview
            16.3.10.2. Drug Class Portfolio
            16.3.10.3. SWOT Analysis
            16.3.10.4. Financial Overview
            16.3.10.5. Strategic Overview
        16.3.11. Svar Life Science
            16.3.11.1. Company Overview
            16.3.11.2. Drug Class Portfolio
            16.3.11.3. SWOT Analysis
            16.3.11.4. Financial Overview
            16.3.11.5. Strategic Overview
        16.3.12. Thermo Fisher Scientific, Inc.
            16.3.12.1. Company Overview
            16.3.12.2. Drug Class Portfolio
            16.3.12.3. SWOT Analysis
            16.3.12.4. Financial Overview
            16.3.12.5. Strategic Overview
        16.3.13. Werfen
            16.3.13.1. Company Overview
            16.3.13.2. Drug Class Portfolio
            16.3.13.3. SWOT Analysis
            16.3.13.4. Financial Overview
            16.3.13.5. Strategic Overview
        16.3.14. SENTINEL CH. SpA
            16.3.14.1. Company Overview
            16.3.14.2. Drug Class Portfolio
            16.3.14.3. SWOT Analysis
            16.3.14.4. Financial Overview
            16.3.14.5. Strategic Overview
        16.3.15. Diazyme Laboratories, Inc.
            16.3.15.1. Company Overview
            16.3.15.2. Drug Class Portfolio
            16.3.15.3. SWOT Analysis
            16.3.15.4. Financial Overview
            16.3.15.5. Strategic Overview
        16.3.16. DiAgam
            16.3.16.1. Company Overview
            16.3.16.2. Drug Class Portfolio
            16.3.16.3. SWOT Analysis
            16.3.16.4. Financial Overview
            16.3.16.5. Strategic Overview

List of Tables

Table 01: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

Table 02: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

Table 03: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 04: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 05: Global Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Region, 2017-2031

Table 06: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country, 2017-2031

Table 07: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

Table 08: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

Table 09: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 10: North America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 11: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 12: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

Table 13: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

Table 14: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 15: Europe Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 16: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 17: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

Table 18: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

Table 19: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 20: Asia Pacific Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 21: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 22: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Patient Type, 2017-2031

Table 23: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

Table 24: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 25: Latin America Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031

Table 26: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

Table 27: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Product Type, 2017-2031

Table 28: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Assay Type, 2017-2031

Table 29: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by Indication, 2017-2031

Table 30: Middle East & Africa Fecal Calprotectin Test Market Value (US$ Mn) Forecast, by End-user, 2017-2031